Ikoma Lyssavirus, Highly Divergent Novel Lyssavirus in an African Civet


Evidence in support of a novel lyssavirus was obtained from brain samples of an African civet in Tanzania. Results of phylogenetic analysis of nucleoprotein gene sequences from representative Lyssavirus species and this novel lyssavirus provided strong empirical evidence that this is a new lyssavirus species, designated Ikoma lyssavirus.

Eleven Lyssavirus species have been classified: Rabies virus (RABV), Lagos bat virus (LBV), Mokola virus (MOKV), Duvenhage virus (DUVV), European bat lyssavirus types -1 and -2, Australian bat lyssavirus, Aravan virus, Khujand virus, Irkut virus, and West Caucasian bat virus (WCBV) (1). All these viruses except MOKV have been detected in bats. Two newly identified lyssaviruses, Shimoni bat virus (SHIBV) (2) and Bokeloh bat lyssavirus (3), both detected in bats, have not yet been classified. The presence of numerous lyssaviruses in bat species has led to increasing research efforts toward lyssavirus discovery in bat populations globally. However, lyssavirus surveillance in terrestrial mammals remains limited across most of Africa.

Of the 13 lyssaviruses, 5 circulate in Africa (RABV, LBV, MOKV, DUVV, and SHIBV). LBV, MOKV, DUVV, and SHIBV are detected exclusively in Africa, whereas RABV is detected worldwide. The predominant RABV variants circulating in Africa are the mongoose and canine biotypes. In South Africa, canine RABV is considered to have been introduced in the eastern Cape Province after importation of an infected dog from England in 1892 and subsequently spread, infecting domestic and wild carnivores (4). Separate introductions of canine RABV (particularly in northern Africa) have been suggested (5). In addition, molecular clock analysis indicates that mongoose RABV was present in southern Africa ≈200 years before the introduction of canine RABV (6).

In Tanzania, canine RABV is endemic and widespread throughout the country. In the Serengeti ecosystem, detailed studies have shown a single variant of canine RABV circulating in multiple host species (7). However, annual mass rabies vaccination campaigns have been conducted for dogs in villages surrounding Serengeti National Park since 2003, and rabies has not been detected in the park since 2000 (8). Enhanced laboratory-based surveillance in support of this canine rabies elimination program has been running concurrently in the region.

The Study

On May 11, 2009, an African civet (Civettictis civetta) displaying clinical signs consistent with rabies was killed by rangers in Ikoma Ward within Serengeti National Park (Figure 1). Rangers were contacted because the civet had bitten a child on the right leg in an unprovoked attack. The wound was washed with soap and water, and the child received postexposure rabies vaccination but no rabies immunoglobulin. Brain samples from the civet were tested multiple times (as part of a training course) at the Central Veterinary Laboratory in Tanzania. Results of the fluorescent antibody test and a direct rapid immunohistochemistry test were positive for lyssavirus-specific antigen. When testing was complete, the samples were sent to the Animal Health and Veterinary Laboratories Agency (AHVLA, Weybridge, UK) for additional confirmation of results and molecular analysis.

RNA was extracted by using TRIzol Reagent (Invitrogen, Paisley, UK), and a pan-lyssavirus reverse transcription PCR yielded a specific 606-bp amplicon (9). The amplicon (GenBank accession no. JN800509) was sequenced by using standard primers and protocols (10). Bayesian reconstructions were used for phylogenetic analysis of the nucleoprotein gene region (405 bp) and included representatives of all species from the lyssavirus genus; results showed that the sequence was unique and most closely related to WCBV (Figure 2). A canine RABV biotype from Tanzania and a mongoose RABV biotype from southern Africa were included in the dataset. Nucleotide comparisons indicated similar divergence from all

 DOI: http://dx.doi.org/10.3201/eid1804.111553

1These data were presented in part at the XXII Rabies in the Americas meeting in San Juan, Puerto Rico, October 16–21, 2011.
Novel Lyssavirus in African Civet

lyssavirus species (minimum identity 62.2% Australian bat lyssavirus, maximum identity 68.6% WCBV), including 12 canine RABV sequences from domestic and wild animals in the Serengeti ecosystem (64.1%–65.1% identity). The posterior probabilities indicated that the IKOV and WCBV grouping was strongly supported, despite low sequence identity. Further phylogenetic analysis of representatives from other rhabdoviruses demonstrated that IKOV is a member of the Lyssavirus genus (41.6%–50.9% identity to representative rhabdovirus sequences that are available for this region of the genome) (data not shown).

Conclusions
We describe evidence, based on genomic sequences obtained from the brain sample of an African civet with clinical signs consistent with rabies, for the existence of a novel lyssavirus designated IKOV (Ikoma lyssavirus). The sample was frozen and thawed several times before being sent to AHVLA, which had a detrimental effect on the sample quality and resulted in viral RNA degradation and loss in viral viability. The results of confirmatory FATs performed at AHVLA were inconclusive, and attempts to isolate virus by using the rabies tissue culture inoculation test and the mouse inoculation test were unsuccessful. Despite the lack of isolated virus, the pan-lyssavirus sensitivity and specificity of the fluorescent antibody test (the test prescribed by the World Organisation for Animal Health as the standard for rabies testing) and direct rapid immunohistochemistry test support the assertion that a novel lyssavirus exists in the region. In addition, despite the poor quality of the sample, molecular techniques identified a lyssavirus-specific amplicon that was confirmed to be unique by phylogenetic analysis and to be highly divergent from known circulating RABV strains. A real-time PCR also detected this unique lyssavirus sequence, confirming that both molecular tests are pan-lyssavirus specific and are sufficient for the detection of highly divergent novel lyssaviruses (11).

The child who was bitten by the African civet received appropriate wound care and postexposure rabies vaccination. At the time of this report, the child remained well. We cannot, however, draw any conclusions as to whether the African civet was shedding virus when it bit the child or whether postexposure vaccinations are effective against IKOV.

This case of rabies in an African civet in the center of Serengeti National Park was highly unexpected. Since
2000, the park had been free of rabies and no cases had been detected within a 30-km radius. This case of rabies in wildlife implied a major breach in the vaccination program. However, subsequent molecular characterization demonstrated that this case of rabies had not been caused by a RABV from a canine source. Thus, a breach had not occurred; instead, a novel lyssavirus with an unknown reservoir had caused the infection. Previously published data on lyssavirus infection in African civets (n = 6) was restricted to the RABV mongoose lineage (12).

Although African civets can be infected with RABV and IKOV, infrequent detection of lyssaviruses in this species suggests that they are more likely to be incidental hosts. The nocturnal, opportunistic foraging behaviors of African civets imply that contact with bats is possible, particularly at roosts where interactions with a grounded rabid bat are more likely to occur. In the absence of virus isolates, the origin of IKOV is difficult to determine. Surveillance for rabies in bats and other mammals in Tanzania and typing of all lyssavirus-positive samples is necessary to determine the distribution and prevalence of IKOV.

The detection of WCBV cross-reacting neutralizing antibodies in gregarious *Miniopterus* spp. bats in neighboring Kenya could be informative, given the strong posterior probability values on the grouping of IKOV and WCBV in the Bayesian analysis (Figure 2) (13). Additional genomic and evolutionary analysis is underway to support IKOV as a new *Lyssavirus* species, potentially grouping with WCBV in phylogroup III (14), and to determine the antigenic diversity of the glycoprotein (15). Given that IKOV is highly distinct from RABV (more genetically distinct than WCBV from RABV) and that a human has been bitten by an infected animal, the effectiveness of current rabies vaccines needs to be further investigated.

Acknowledgments

We are grateful to the Tanzania Wildlife Research Institute, Tanzania Commission for Science and Technology, Tanzania National Parks, the Ngorongoro Conservation Area Authority, and the National Institute for Medical Research for permissions. We thank Tanzania National Parks, the Ngorongoro Conservation Area, Tanzania Commission for Science and Technology, Tanzania for their technical support. Emma Wise, Colin Black, Lillian Orciari, and Michael Niezgoda for field support and the Ministry of Livestock and Fisheries Development for laboratory support in Tanzania. We also thank Sarah Devery, Stacey Leech, Emma Wise, Colin Black, Lillian Orciari, and Michael Niezgoda for their technical support.

This work was partially supported by The Department for Environment, Food and Rural Affairs ROAME SE0423/SV3500, by the EU FP7-funded Research Infrastructure Grant European Virus Archive (no. 228292), and by the Research and Policy for Infectious Disease Dynamics program of the Science and Technology Directorate (US Department of Homeland Security), and the Fogarty International Center. In Tanzania, the work was funded by Lincoln Park Zoo (Chicago, IL, USA), the Wellcome Trust, UBS Optimus Foundation, and the Medical Research Council.

Mrs Marston is a research scientist at AHVLA. Her research interests include viral genetics, molecular epidemiology, and virus–host interactions.

References


Address for correspondence: Anthony R. Fooks, Wildlife Zoonoses and Vector-borne Diseases Research Group, Animal Health and Veterinary Laboratories Agency, New Haw, Addlestone, Surrey, KT15 3NB, UK; email: tony.fooks@ahvla.gsi.gov.uk